Keyword: Caribou Biosciences
University of California starts its fightback against rival Broad Institute in their dispute over intellectual property for CRISPR-Cas9.
Stada replaced its CEO and CFO as Bain and Cinven prepare for new bid, ex-Alexion head David Hallal joined Scholar Rock as chairman, Caribou named CSO.
Caribou has seen biopharma vet and former Arrowhead exec Steven Kanner join the biotech.
After Editas and Intellia went public this year, CRISPR has brought up the rear with its IPO. But the biotech will need to gear up for a tough market that has seen its rivals’ stock fall hard in the intervening months, and the ongoing patent saga on who “owns” the gene editing tech.
Caribou Biosciences has discovered patterns in the way different cell types respond to being cut via CRISPR-Cas9 genome editing.
One of the central players involved in sparking the gene editing boom has added a $30 million B round to its reserves.